TRDA Entrada Therapeutics, Inc: Year-over-year earnings per share growth for the last twelve months

Official company branding of Entrada Therapeutics, Inc. (TRDA)

A comparison of quarterly EPS demonstrates the dynamics of Entrada Therapeutics (TRDA), whose US laboratories develop drugs for rare neuromuscular pathologies. The technological base allows for the scaling of drug delivery across multiple diseases, attracting capital from industry behemoths. However, the current investment stage requires significant testing expenditures, increasing unit costs. The value of 11.70 represents the latest metric reading.

Entrada Therapeutics, Inc. (TRDA) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/15/2026

Analytical breakdowns for Entrada Therapeutics

- share price and consensus valuation forecast:
Fundamental company analysis:entradatx.com, TRDA
Manufactured product of Entrada Therapeutics, Inc

The stability of Entrada Therapeutics (TRDA) is driven by the integration of robotic synthesis and expert quality control of its drugs. Quarterly EPS growth measures the change in net income per share, reflecting the efficiency of capital management. Investors analyze this pace to rule out speculative overheating of the asset. The GURU.Markets toolkit allows for tracking the company's adaptation to market rules. The quarterly EPS trend profile visualizes the issuer's actual financial resilience.

Analysis of competing companies

JAZZ (Jazz Pharmaceuticals PLC) - Year-over-year net earnings per share growth for the last 12 months|Cytokinetics Corp (CYTK) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months PTC Therapeutics, Inc.|SRRK: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Centessa Corp (CNTA)|Year-over-year earnings per share growth for the last twelve months DYN (Dyne Therapeutics Inc)|Year-over-year earnings per share growth for the last twelve months Edgewise Pharma EWTX|Rapport Corp - Year-over-year earnings per share growth for the last twelve months|ALMS - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Zevra Therapeutics|CTNM: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Larimar Pharma LRMR|Year-over-year net earnings per share growth for the last 12 months CAPR|Earnings per share growth in annualized terms for the last twelve months Channel PTHS|Year-over-year earnings per share growth for the last twelve months MediciNova Inc. (MNOV)|SER - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth BTAI (BioXcel Therapeutics Inc)|ProMIS Neurosciences (PMN) - Earnings per share growth in annualized terms for the last twelve months|Apimeds Pharmaceuticals, Inc. - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months AEON Biopharma, Inc.|NLSP (NLS Pharma) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last 12 months BNOX|Year-over-year earnings per share growth for the last twelve months FSD Pharma|Quarterly EPS earnings growth Reata